Obstructive Laryngitis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Obstructive Laryngitis Treatment Market is Segmented By Medication (Glucocorticoid, Dexamethasone,  Epinephrine, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Obstructive Laryngitis Treatment Market Overview

Obstructive Laryngitis Treatment Market size is growing at a high CAGR during the forecast period (2024-2031).

Overuse, irritation, or infection can cause laryngitis and inflammation of the voice box (larynx). A virus is the most common cause of laryngitis.

As per DataM Intelligence, Obstructive Laryngitis Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Obstructive Laryngitis Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Obstructive Laryngitis Treatment Market in the United States and Canada produces the utmost share. Whereas the European Obstructive Laryngitis Treatment Market is projected to continue its presence globally during the period of 2024-2031.

Obstructive Laryngitis Treatment Market Scope

To Know More Insights - Download Sample

Obstructive Laryngitis Treatment Market Dynamics

The factors influencing the global obstructive laryngitis treatment market are the increasing research and development for the treatment and the growing prevalence of obstructive laryngitis.

The increasing research and development for the treatment of obstructive laryngitis is expected to drive the market growth in the forecast period

Croup is a common respiratory infection that affects 3% of children aged six months to three years. It accounts for 7% of annual hospitalizations in children under five for fever and acute respiratory illness. Croup is an upper airway obstruction caused by swelling of the larynx, trachea, and bronchi, which results in inspiratory stridor and a barking cough. Low-grade fevers are common in patients, but they are not required for diagnosis. In patients with croup of any severity, corticosteroids should be used. Dexamethasone treatment leads to a faster resolution of symptoms and a lower need for medical attention. Corticosteroids are thought to work by reducing edema in the laryngeal mucosa due to their anti-inflammatory properties. A study found that corticosteroid treatment improved symptom scores at six and twelve hours (dexamethasone, budesonide [Rhinocort], or methylprednisolone).

Moreover, there are three types of acute obstructive laryngitis in children Epiglottitis acute (acute supraglottic laryngitis): Hemophilus influenza type B is the most common causative organism. A swollen red epiglottis is a characteristic finding. Ampicillin, Solucortef (hydrocortisone-sodium succinate) i.m., air humidification, intravenous infusions, and airway protection are used in the treatment (tracheotomy or intubation).

Limitations related to the treatment are expected to hamper the market growth

Acute laryngitis usually improves on its own after a week or so. Self-care measures like voice rest, drinking plenty of water, and humidifying your air can also help alleviate symptoms. Chronic laryngitis treatments target the condition's underlying causes, such as heartburn, smoking, or excessive alcohol consumption, and are limited. For instance, in some cases, medications such as antibiotics are ineffective in almost all cases of laryngitis because the cause is almost always viral. The doctor may prescribe an antibiotic if one has a bacterial infection. Corticosteroids can help reduce vocal cord inflammation in some cases. However, this treatment is only used when laryngitis is urgently needed, such as in some cases of croup-associated laryngitis in toddlers. All medications can cause side effects, which vary depending on the medication. OTC pain relievers are not only the most effective treatment for laryngitis symptoms, but they are also extremely safe. Acetaminophen can cause nausea, headaches, and stomach pain, but overdosing is the most dangerous side effect. More is not better for acetaminophen, so stick to the instructions. Also, check for acetaminophen in other OTC products such as cough and cold medicines. People frequently overdose by taking too much acetaminophen from multiple OTC products.

COVID-19 Impact Analysis

Inflammation of the vocal cords is referred to as laryngitis. When a person has laryngitis, they may notice changes in their voice and pain when speaking or swallowing. These symptoms may occur in people who have COVID-19. COVID-19 can cause laryngitis, as well as other factors like smoking. The vocal cords, which are bands of tissue that vibrate to generate vocal sounds, are inflamed by laryngitis. Voice changes, throat pain, and difficulty swallowing or speaking can be symptoms of inflamed vocal cords. COVID-19 patients may experience these symptoms because of the disease. The most common cause of laryngitis is a virus. Long COVID occurs when symptoms last for at least four weeks, according to the Centers for Disease Control and Prevention (CDC)Trusted Source. The Centers for Disease Control and Prevention (CDC) does not list laryngitis as a common long-term complication of COVID-19 but acknowledges the lack of research in this area.

Obstructive Laryngitis Treatment Market Segment Analysis

Glucocorticoid segment is expected to dominate the market growth

Acute obstructive laryngitis (AOL) is one of the most common respiratory diseases in children, affecting primarily children aged 6 months to 6 years old and occurring more frequently in late autumn and early winter. They are usually minor and self-limiting, but they can occasionally result in severe respiratory obstruction. By reducing the local inflammatory response, contracting lymphoid inflammation, and impairing capillary permeability, systemic corticosteroids reduce laryngeal edema. They have been one of the pillars of treatment in croup patients due to their potent anti-inflammatory effect. However, there is some uncertainty about the magnitude of the advantages. Systemic corticosteroids reduce the risk of readmission in children with acute obstructive laryngitis.

 Anti-inflammatory properties of glucocorticoids are thought to reduce inflammation and swelling, resulting in less effort in breathing for the child. According to an updated 2018 Cochrane Review, glucocorticoids (prednisone, dexamethasone) reduced croup symptoms in 2 hours, shortened hospital stays, and reduced the rate of patient care return visits. The previous version of the Cochrane Review stated that glucocorticoids reduced croup symptoms within 6 hours of administration. If given within the first 4-24 hours after the onset of the illness, a single dose of dexamethasone has been shown to reduce the overall severity of croup. Dexamethasone's long half-life (36-54 hours) allows for a single injection or dose to cover the typical croup symptom duration.

Obstructive Laryngitis Treatment Market Geographical Share

North America region is expected to hold the largest market share in the global obstructive laryngitis treatment market

The increasing prevalence of obstructive laryngitis and the growing research and development is expected to drive the market growth in this region.

Croup is a common respiratory illness characterized by inspiratory stridor and barking cough that affects the larynx, trachea, and bronchi. Croup includes laryngotracheitis, laryngotracheobronchitis, and laryngotracheobronchopneumonitis, affecting 3% of children aged six months to three years. Croup accounts for 7% of hospitalizations for fever and/or acute respiratory illness in children under five in the United States each year. In the United States, obstructive laryngitis is responsible for nearly 8% of hospitalizations in children under five.

Obstructive Laryngitis Treatment Market Companies and Competitive Landscape

Obstructive laryngitis treatment market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Lannett Company, Inc., Teva Pharmaceuticals USA, Inc., Lannett Company, Inc., Akorn Inc., and Pfizer Inc.

Teva Pharmaceuticals USA, Inc.

Overview: The company's primary business is generic drugs, but it also deals in active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. The company was founded in 1985.

Product Portfolio: The company manufactures Deltasone Tablets. They are prednisone tablets; USP contains the glucocorticoid prednisone. For severe laryngitis cases, a physician may prescribe an oral or inhaled corticosteroid, such as prednisone, or voice professionals to reduce swelling quickly.